Adverse effect · KPV

How common is safety in humans with KPV?

D
Grade D — no human evidenceNone · effect size: not measurable · adverse
Short answerNo human evidence. As of 3 September 2026, only none exist for KPV for safety in humans. No human dosing study exists, so there is no safety dataset at any dose or route.

What the studies show

No human dosing study exists, so there is no safety dataset at any dose or route.

Animal studies, cell studies, or anecdotes only. This is where almost every viral peptide sits. Promising and proven are different words for a reason.

In context

KPV is a three-amino-acid fragment (lysine-proline-valine) from the tail of the hormone α-MSH, studied for anti-inflammatory effects. In cell and mouse models of gut inflammation it dampens inflammatory signalling, which is the basis of its reputation for 'healing' and gut health. No controlled human trial of any kind has tested it. It is not approved anywhere.

KPV is not approved. Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is KPV proven to cause safety in humans?
No. There is no human evidence for it (None); the claim rests on animal or cell studies and LYO grades it D.
What studies are behind the grade?
No human dosing study exists, so there is no safety dataset at any dose or route.
Is KPV approved for this?
No. KPV is not approved; it is not an approved medicine for any indication in the jurisdictions LYO covers.

Other outcomes for KPV

Written and maintained by LYO Research — how pages are written and checked. Reviewed 3 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →